Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
5.26
-0.09 (-1.68%)
At close: Feb 27, 2025, 4:00 PM
4.280
-0.980 (-18.63%)
After-hours: Feb 27, 2025, 7:59 PM EST
Iovance Biotherapeutics Revenue
In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth. Iovance Biotherapeutics had revenue of $73.69M in the quarter ending December 31, 2024, with 15,189.21% growth.
Revenue (ttm)
$164.07M
Revenue Growth
+13,698.99%
P/S Ratio
9.29
Revenue / Employee
$294,560
Employees
557
Market Cap
1.60B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IOVA News
- 5 hours ago - Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 hours ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 9 days ago - Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025 - GlobeNewsWire
- 15 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - GlobeNewsWire
- 6 weeks ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 7 weeks ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 3 months ago - Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewsWire